A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 557 participants.

Also called NCT06215911

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 557 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06215911
  • EudraCT 2023-508736-62
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Belgium, Bulgaria, Canada, Czechia, Georgia, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, New Zealand, Poland, Slovakia, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06215911. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-13 (actual); primary completion 2025-10-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
Acronym
Cycle-1-REF
Condition
Heart Failure
Condition
Cardiovascular Diseases
Condition
Heart Diseases
Intervention (Drug)
Tovinontrine (CRD-750)
Intervention (Drug)
Placebo
Lead sponsor
Cardurion Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06215911
Content hash
b1a56c10b6bd7fa6bb06d4709441181c7f92d48250ed174cc87123721d2a178c